NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, open-lable phase III clinical trial evaluating the
effectiveness and safety of vinorelbine plus capecitabine as adjuvant treatment for non-pCR
Luminal B breast cancer patients after standard neoadjuvant chemotherapy.